bioAffinity Technologies appoints Roberto Rios and John Oppenheimer to board; Gary Rubin resigns

bioAffinity Technologies, Inc.

Roberto Rios (CPA) and John J. Oppenheimer (M.D.) appointed to Board, each term expiring at 2026 annual meeting.
Gary Rubin resigned from Board and Nominating Committee effective Aug. 12, 2025, not due to any disagreement.
Rios appointed Chair of Audit Committee and member of Compensation Committee; Oppenheimer on Nominating and Governance Committee.
Jamie Platt appointed to Audit Committee and as Chair of Nominating and Governance Committee; Robert Anderson on Compensation Committee.
New directors bring expertise in finance (Rios) and clinical respiratory research (Oppenheimer) to support CyPath Lung sales and pipeline.

item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.